Analyst Rating Update on Hologic (HOLX)

Hologic (HOLX) has an average broker rating of 1.88, which is interpreted as a Buy, as rated by 16 equity analysts. Nonetheless, 9 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Hologic (HOLX) : The most positive equity analysts on Hologic (HOLX) expects the shares to touch $46, whereas, the least positive believes that the stock will trade at $39 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $42.33 with an expected fluctuation of $2.42 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Evercore ISI Group upgrades the rating on Hologic (NASDAQ:HOLX). The brokerage firm has issued a Buy rating on the shares. The shares were previously rated Hold. The rating by the firm was issued on July 28, 2016.


Hologic (NASDAQ:HOLX): The stock opened at $38.99 on Wednesday but the bulls could not build on the opening and the stock topped out at $39.15 for the day. The stock traded down to $38.88 during the day, due to lack of any buying support eventually closed down at $39.00 with a loss of -0.08% for the day. The stock had closed at $39.03 on the previous day. The total traded volume was 3,586,335 shares.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.